GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » Buyback Yield %

MYNZ (Mainz Biomed NV) Buyback Yield % : -192.41 (As of Apr. 18, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Mainz Biomed NV's current buyback yield was -192.41%.


Mainz Biomed NV Buyback Yield % Historical Data

The historical data trend for Mainz Biomed NV's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Buyback Yield % Chart

Mainz Biomed NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial - -8.36 -22.96 -26.05 -143.40

Mainz Biomed NV Quarterly Data
Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.53 -3.87 -26.05 -43.82 -143.40

Competitive Comparison of Mainz Biomed NV's Buyback Yield %

For the Diagnostics & Research subindustry, Mainz Biomed NV's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mainz Biomed NV's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mainz Biomed NV's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Mainz Biomed NV's Buyback Yield % falls into.


;
;

Mainz Biomed NV Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Mainz Biomed NV's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 13.765) / 9.59904
=-143.40%

Mainz Biomed NV's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 13.765) / 9.59904
=-143.40%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Mainz Biomed NV Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mainz Biomed NV Business Description

Traded in Other Exchanges
N/A
Address
Robert Koch Strasse 5, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.